Medicare Costs for Semaglutide Under New Price Agreements Analyzed

Semaglutide, a highly effective GLP-1 receptor agonist, is approved for treating type 2 diabetes and obesity. Its rising utilization presents significant cost implications for public health programs like Medicare. This study specifically examines the potential financial impact of voluntary price agreements on Medicare Part D spending for Semaglutide.

The analysis revealed substantial variations in projected Medicare spending depending on the implemented price agreements and utilization. Under a baseline scenario without price agreements, Medicare Part D spending on Semaglutide was projected to reach $150 billion over 10 years. However, with a 25% voluntary price reduction, projected spending decreased by $37.5 billion, resulting in a total of $112.5 billion. > A 35% price reduction scenario, coupled with a 7% utilization rate, could lead to Medicare savings of up to $52.5 billion over the decade, reducing total spending to $97.5 billion. Conversely, higher utilization rates (e.g., 10% of eligible beneficiaries) without significant price concessions could escalate spending to $200 billion, even with modest discounts. The study also estimated that beneficiary out-of-pocket costs could decrease by an average of $500 per year under optimal price agreement scenarios.